HemaCore Labs

  • Grant accepted

Project

Thrombodynamics-4D – new innovative global coagulation assay, highly sensitive both to hypercoagulation and to hypocoagulation states.

  • Reveals patients with high thrombotic or bleeding risks
  • Can be used for monitoring of efficacy and safety of anticoagulant therapy (including new oral anticoagulants)
  • Easy for understanding and interpretation

Thrombodynamics method mimics (in vitro) coagulation process developed within a blood vessel at the site of injury and registers spatial dynamics of clot growth and thrombin generation:

  • Reconstruction of blood vessel wall damage in vitro
  • Physiological activation of coagulation
  • Real-time observation of fibrin clot propagation and thrombin generation

Company

HemaCore Labs was founded in 2012 as a biotech company and headquartered in Russia, Moscow. We focus on developing, manufacturing and implementing into clinical practice new in vitro diagnostics for hemostasis – Thrombodynamics-4D.

Thrombodynamics-4D assay – a new highly sensitive test for monitoring and risk assessment of blood coagulation disorders – bleeding and thrombosis.

We help physicians who deal with patients with thrombotic or bleeding risks succeed providing clear and reliable estimation of patient’s coagulation state, thus preventing thrombotic or bleeding complications. Unlike current diagnostic coagulation assays, Thrombodynamics-4D assay, being based on a cutting edge 4D-biochemistry technology, can be used for estimation of severity of procoagulant changes and precise control of anticoagulant therapy as demonstrated by clinical studies and our clients experience.


Team [3]